Towards a Greener IBD-Care: Let's INTERACT!
作者信息
Louis Stephanie, Lembrechts Nikki, Pouillon Lieven
机构信息
Department of Gastroenterology and Hepatology, Imelda General Hospital, Imelda GI Clinical Research Unit, Bonheiden, Belgium.
出版信息
United European Gastroenterol J. 2025 Mar;13(2):276-277. doi: 10.1002/ueg2.12728. Epub 2024 Dec 4.
Abstract
摘要
相似文献
1
Towards a Greener IBD-Care: Let's INTERACT!迈向更环保的炎症性肠病护理：让我们互动起来！
United European Gastroenterol J. 2025 Mar;13(2):276-277. doi: 10.1002/ueg2.12728. Epub 2024 Dec 4.
2
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.2018年炎症性肠病对加拿大的影响：直接成本与医疗服务利用情况
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
3
The cost of illness analysis of inflammatory bowel disease.炎症性肠病的疾病经济负担分析。
BMC Gastroenterol. 2023 Jan 19;23(1):21. doi: 10.1186/s12876-023-02648-z.
4
Prevalence of inflammatory bowel disease in an insured population in Puerto Rico during 1996.1996年波多黎各参保人群中炎症性肠病的患病率。
P R Health Sci J. 2003 Sep;22(3):253-8.
5
Prevalence of inflammatory bowel disease in the Australian general practice population: A cross-sectional study.澳大利亚普通人群中炎症性肠病的流行情况：一项横断面研究。
PLoS One. 2021 May 27;16(5):e0252458. doi: 10.1371/journal.pone.0252458. eCollection 2021.
6
Finger clubbing in inflammatory bowel disease: association with upper small bowel lesions and need of surgery in Crohn's disease.炎症性肠病中的杵状指：与克罗恩病的上小肠病变和手术需求相关。
Eur J Gastroenterol Hepatol. 2021 Jun 1;33(6):844-851. doi: 10.1097/MEG.0000000000001966.
7
Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.通过RAND方法评估炎症性肠病中免疫抑制药物的适用性：意大利炎症性肠病研究小组（IG-IBD）立场声明
Dig Liver Dis. 2005 Jun;37(6):407-17. doi: 10.1016/j.dld.2004.12.013.
8
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.维多珠单抗用于儿童炎症性肠病的维持治疗（VEDOKIDS）：一项多中心、前瞻性队列研究的54周结果
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
9
Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland.瑞士炎症性肠病相关住院前 12 个月治疗模式和医疗保健使用的系统分析。
Eur J Gastroenterol Hepatol. 2020 Mar;32(3):350-357. doi: 10.1097/MEG.0000000000001616.
10
The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation.炎症性肠病的成本：来自克罗恩病和结肠炎基金会的倡议。
Inflamm Bowel Dis. 2020 Jan 1;26(1):1-10. doi: 10.1093/ibd/izz104.
本文引用的文献
1
The United European Gastroenterology green paper-climate change and gastroenterology.欧洲胃肠病学会绿皮书-气候变化与胃肠病学。
United European Gastroenterol J. 2024 Nov;12(9):1292-1305. doi: 10.1002/ueg2.12698. Epub 2024 Oct 25.
2
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
3
Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial.炎症性肠病管理的远程医疗（myIBDcoach）：一项实用的、多中心、随机对照试验。
Lancet. 2017 Sep 2;390(10098):959-968. doi: 10.1016/S0140-6736(17)31327-2. Epub 2017 Jul 14.
Zotero 插件